A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

• Status: Completed
• Trial end date: 2010-07-05
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and distribution of both PF-04447943 and donepezil.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Subjects must have Alzheimer's dementia with a Mini Mental State Examination score between 18-26, inclusive.

• Subjects must have a reliable caregiver.

• Subjects must be on Aricept

• Memantine is allowed if subjects are on a stable dose

• Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG, with no serious or unstable disease within the past 3 months.

Exclusion Criteria:

• Subjects with clinically significant heart disease cannot participate.

• Subjects with a past or current history of seizures cannot participate.